Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Andrographolide, a diterpenoid lactone isolated from Andrographis paniculata, has a traditional history of use in Southeast Asian and Indian herbal medicine for infectious diseases, including febrile illnesses such as malaria. However, its use for malaria is not solely based on tradition; there is some scientific investigation into its antimalarial properties. In vitro studies have demonstrated that andrographolide and its derivatives exhibit inhibitory effects on Plasmodium falciparum, the parasite responsible for the most severe form of malaria. For example, research published in Parasitology Research (2012) and other pharmacological journals has shown moderate activity against both chloroquine-sensitive and -resistant strains of the parasite in laboratory settings.

Animal studies (in vivo) have also reported reduced parasitemia in rodent models following administration of andrographolide. However, these effects are generally less potent than standard antimalarial drugs such as chloroquine or artemisinin. Human clinical trials evaluating andrographolide for malaria are lacking, and its efficacy and safety profile for this specific condition remain unproven in clinical settings. Thus, while there is preliminary scientific validation from laboratory and preclinical research, the overall quality and quantity of evidence are limited, and it is not regarded as a frontline or recommended therapy for malaria.

In summary, andrographolide's use for malaria is supported by some scientific studies, but the evidence is preliminary (rating 2/5) and insufficient to warrant its use as a primary treatment for malaria.

More about Andrographolide
More about Malaria

Other ingredients used for Malaria

Other health conditions supported by Andrographolide

Products containing Andrographolide